Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The recent indication in an article by Nissen, et al (N Engl J Med. 2007;356:2457-2471) that rosiglitazone (ROSI) might actually increase cardiovascular (CV) risk was met with surprise and dismay by many clinicians and their patients alike.

Clinical Briefs By Louis Kuritzky, MD